We are live on ! Find out more
PAVM icon

PAVmed
PAVM

3 hedge funds and large institutions have $312K invested in PAVmed in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,166% more capital invested

Capital invested by funds: $7.31K → $312K (+$305K)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$4.19K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCS
1
Levin Capital Strategies
New York
$155K – – –
MSAM
2
Moloney Securities Asset Management
Missouri
$152K +$205K +49 New
TRCT
3
Tower Research Capital (TRC)
New York
$5K +$4.19K +1 +100%
UBS Group
4
UBS Group
Switzerland
– -$4K -1 Closed

PAVM Hedge Fund Activity: Q4 2016 in Review

3 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q4 2016, worth a combined $312K — up 4,166% from $7.31K a quarter earlier.

Fund positioning in PAVM was balanced in Q4 2016: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Tower Research Capital (TRC), adding an estimated $4.19K. The largest seller was UBS Group, exiting entirely with an estimated $4K sold.

  • 3 institutional investors held PAVmed (PAVM) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $312K of PAVmed stock for Q4 2016, up 4,166% quarter-over-quarter.
  • 1 fund opened new PAVmed positions in Q4 2016 and 1 closed out, a net change of 0 holders.
  • The largest PAVmed buyer in Q4 2016 was Tower Research Capital (TRC), an estimated $4.19K added.
  • The largest PAVmed seller in Q4 2016 was UBS Group, an estimated $4K sold.

Based on aggregated 13F filings for Q4 2016.